title: PCSK9 Inhibitors May Show Benefits of Ultra-Low LDL Levels.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reinke
mesh_terms: D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D055118:Medication Adherence; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors* / Q000191:economics; D012697:Serine Endopeptidases / Q000191:economics
chemical_list: D000924:Anticholesteremic Agents; D008077:Lipoproteins, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases